iifl-logo-icon 1

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Biocon's Liraglutide Approval Spurs Stock Rise, Eyes UK Market Expansion

28 Mar 2024 , 03:02 PM

Biocon’s stock rose by 1.54% to reach ₹260.55 following the announcement of approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K., for its complex formulation Liraglutide.

The application for Liraglutide was filed by Biocon through its European partner, Zentiva. Liraglutide, a drug-device combination formulation, is used in treating Type-2 Diabetes Mellitus, a condition characterized by insufficient insulin production or response, leading to high blood sugar levels.

According to IQVIA MAT Q4 2023, the total addressable market opportunity for GLP-1 in diabetes and weight loss in the U.K. amounts to US $425 million.

Siddharth Mittal, CEO and MD of Biocon, emphasized the significance of Liraglutide’s approval, highlighting it as a key milestone and the first generic Liraglutide approved in a major regulated/ICH market.

Mittal expressed confidence in Biocon’s capability to deliver pioneering complex drug products like bTrastuzumab, bPegfilgrastim, and the first interchangeable biosimilar Insulin Glargine, approved by the U.S. FDA.

Biocon’s focus on GLPs and peptides as vital growth drivers for the generics business was underscored, with plans to swiftly commercialize Liraglutide in the U.K. in partnership with Zentiva.

Biocon, an innovation-led global biopharmaceuticals company, specializes in therapies for chronic conditions such as diabetes, cancer, and autoimmune disorders, with a diverse portfolio of biologics, biosimilars, and small molecule APIs.

In Q3 FY24, Biocon reported a consolidated net profit of ₹660 Crore, a significant improvement compared to the net loss of ₹41.8 Crore in Q3 FY23. Revenue from operations surged by 34.43% YoY to ₹3,953.7 Crore in the quarter ended December 31, 2023.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Biocon
  • Company news
  • UK Market Expansion
sidebar mobile


Read More

Most Read News

Indian markets close on a positive note
14 Jun 2024|06:41 PM
Sensex and Nifty Surge
14 Jun 2024|06:43 PM
LIC stock price up by more than 5% today
14 Jun 2024|06:44 PM
Read More
Knowledge Centerplus

Logo IIFL Customer Care Number
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

Knowledge Centerplus

Follow us on


2024, IIFL Securities Ltd. All Rights Reserved

  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.